110 related articles for article (PubMed ID: 8007520)
21. [Evaluation of clinical efficacy of isoniazid and ethambutol in the treatment of nontuberculous mycobacteriosis based on in vitro susceptibility testing].
Tsukamura M
Kekkaku; 1989 Aug; 64(8):511-8. PubMed ID: 2811008
[TBL] [Abstract][Full Text] [Related]
22. In-vitro activity of quinolones and macrolides against mycobacteria.
Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
[TBL] [Abstract][Full Text] [Related]
23. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
Barrett MS; Jones RN; Erwin ME; Koontz FP
Diagn Microbiol Infect Dis; 1992 Feb; 15(2):169-71. PubMed ID: 1315233
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and bacteriological study of sparfloxacin on bacterial prostatitis].
Suzuki K; Horiba M; Naide Y; Shinoda M; Hibi H
Hinyokika Kiyo; 1992 Jan; 38(1):121-8. PubMed ID: 1312292
[TBL] [Abstract][Full Text] [Related]
25. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
Mizutani S
Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
[TBL] [Abstract][Full Text] [Related]
26. Activity of quinolones against mycobacteria.
Jacobs MR
Drugs; 1999; 58 Suppl 2():19-22. PubMed ID: 10553700
[TBL] [Abstract][Full Text] [Related]
27. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis.
Lefèvre JC; Escaffre MC; Courdil M; Lareng MB
Pathol Biol (Paris); 1993 Apr; 41(4):313-5. PubMed ID: 8233628
[TBL] [Abstract][Full Text] [Related]
28. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.
Saito H; Tomioka H; Sato K; Emori M; Yamane T; Yamashita K; Hosoe K; Hidaka T
Antimicrob Agents Chemother; 1991 Mar; 35(3):542-7. PubMed ID: 2039206
[TBL] [Abstract][Full Text] [Related]
29. Minimal inhibitory concentrations of lomefloxacin and minocycline against drug-sensitive and drug-resistant isolates of M. tuberculosis compared on L-J and 7H11 media.
Kamala T; Herbert D; Venkatesan P; Paramasivan CN
Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):375-8. PubMed ID: 9401493
[TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility of Mycobacterium kansasii to the difluorinated quinolone sparfloxacin using a broth microdilution and macrodilution MIC system.
Royo P; Martín-Casabona N; Martínez E; Andonegui M
Int J Tuberc Lung Dis; 1999 Apr; 3(4):349-53. PubMed ID: 10206507
[TBL] [Abstract][Full Text] [Related]
31. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria.
Guillemin I; Jarlier V; Cambau E
Antimicrob Agents Chemother; 1998 Aug; 42(8):2084-8. PubMed ID: 9687411
[TBL] [Abstract][Full Text] [Related]
32. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.
Young LS; Berlin OG; Inderlied CB
Am J Med; 1987 Apr; 82(4A):23-6. PubMed ID: 3107379
[TBL] [Abstract][Full Text] [Related]
33. [Reactivities of various mycobacteria species against DNA probes (Gen-Probe Rapid Diagnostic System) specific to Mycobacterium tuberculosis complex, Mycobacterium avium and Mycobacterium intracellulare].
Tomioka H; Sato K; Saito H; Tasaka H
Kekkaku; 1991 Jun; 66(6):405-11. PubMed ID: 1942722
[TBL] [Abstract][Full Text] [Related]
34. N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
Klopman G; Fercu D; Renau TE; Jacobs MR
Antimicrob Agents Chemother; 1996 Nov; 40(11):2637-43. PubMed ID: 8913479
[TBL] [Abstract][Full Text] [Related]
35. Activity of quinolones against mycobacteria.
Jacobs MR
Drugs; 1995; 49 Suppl 2():67-75. PubMed ID: 8549419
[TBL] [Abstract][Full Text] [Related]
36. In vitro evaluation of various quinolone antibacterial agents against veterinary mycoplasmas and porcine respiratory bacterial pathogens.
Hannan PC; O'Hanlon PJ; Rogers NH
Res Vet Sci; 1989 Mar; 46(2):202-11. PubMed ID: 2704885
[TBL] [Abstract][Full Text] [Related]
37. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119
[TBL] [Abstract][Full Text] [Related]
38. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium].
Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K
Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866
[TBL] [Abstract][Full Text] [Related]
39. Antituberculosis agents. VI. Activity of a new ciprofloxacin derivative against Mycobacterium avium and some drug-resistant strains of Mycobacterium tuberculosis.
Foroumadi A; Soltani F; Moshafi MH
Boll Chim Farm; 2002; 141(5):394-6. PubMed ID: 12481384
[TBL] [Abstract][Full Text] [Related]
40. Determination of the minimal effective dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system.
Traore I; Ji B; Lienhardt C; Bobin P; Grosset J
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):142-5. PubMed ID: 8690973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
